Kornimate/medical-research-clean huggingface dataset:
stereotactic body radiotherapy and surgery for early-stage hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma; Hepatectomy; Stereotactic Body Radiotherapy

Summary: the prognosis of small liver cancer (≤5 cm) with stereotactic body radiotherapy (sbrt) is encouraging, the 1-year local control rate has been reported to be 95-100%, 3-year local control rate about 91%, and 3-year overall survival rate around 70%. so far, there is no randomized controlled study comparing sbrt and surgical treatment for early-stage liver cancer. it is hoped that this study will further compare the efficacy of sbrt and surgery for early stage liver cancer.

early stage liver cancer, according to milan criteria, are chose for this study. the patients are divided into two groups randomly. patients in group a receive laparoscopic hepatectomy, group b patients receive sbrt.the 3-year progression free survival, 3-year local recurrence free survival, 3- year overall survival and other endpoints events were recorded and analyzed, to assess whether sbrt is non-inferior to surgery.

Eligibility criteria:
inclusion criteria: 1. 18 years old and above. 2. clinical or pathological diagnosis of hepatocellular carcinoma, initial treatment (without surgery, radiotherapy, chemotherapy or targeted therapy). 3. early-stage hepatocellular carcinoma meeting the milan criteria: single lesion ≤ 5cm, or tumor number ≤ 3, maximum diameter ≤ 3cm, no major vascular invasion of portal vein, hepatic vein, inferior vena cava, no bile duct invasion, no lymph node and extrahepatic metastasis. 4. no serious blood system, heart, lung, liver, kidney dysfunction and immune deficiency. 5. the neutrophil count is at least 1.0\*10\^9/ml, and the platelet count is at least 50\*10\^9/ml. hemoglobin is at least 80g/l. 6. men or women with fertility are willing to take contraceptive measures during the trial. 7. eastern cooperative oncology group score 0-1 points. 8. expected survival period \> 3 months. 9. voluntary participation and signing of informed consent. exclusion criteria: 1. patients who have undergone chemoradiation or targeted therapy for liver cancer. 2. recent hematemesis due to portal hypertension. 3. child-pugh score ≥10 points. 4. total bilirubin\>70umol/l, aspartate aminotransferase (alt), alanine aminotransferase (ast) exceed the upper limit of normal 3 times. 5. who was considered unsuitable for surgery after hepatobiliary and pancreas multidisciplinary treatment（mdt） meeting. 6. patients undergoing major surgery within 1 month of study initiation 7. patients with previous history of malignancy (excludes tumor-free survival after treatment of basal cell carcinoma of the skin and carcinoma of the cervix in situ for more than 3 years) 8. researchers consider it inappropriate to participate in the test

Keywords: hepatocellular carcinoma early-stage liver cancer hepatectomy stereotactic body radiotherapy
assessing brain changes throughout the abi wellness program

Conditions: Brain Injuries

Summary: symptoms resulting from mild/moderate trauma to the brain are as varied as the individuals who sustain them. the currently held belief is that the majority of healing and functional recovery occurs within the first two years post injury. a large proportion of individuals who sustain mild/moderate brain injuries (mtbis) do not fully recover, and continue to experience symptoms well beyond two years post injury. cognitive rehabilitation programs have been shown to be somewhat effective in helping mtbi patients regain some functionality in these executive domains. the purpose of the current study is to use an objective assessment of brain function to track changes during either a full-time or part-time holistic cognitive rehabilitation program, specifically the abi wellness (abiw) program. the neurocatch platform™ test will be used to assess brain functioning before, during and after 3 months in the abiw program. the neurocatch platform™ test uses electroencephalography (eeg) to measure event-related potential (erp) signals produced by the brain, in response to an auditory stimulus. three brain processes are examined with this test: auditory sensation (erp marker is the n100), basic attention (erp marker is the p300), and cognitive processing (erp marker is the n400).


Eligibility criteria:
inclusion criteria: 1. enrolled in but not initiated the abi wellness program 2. male or female, 19-65 years old inclusively 3. normal hearing capabilities 4. able to understand the informed consent form, study procedures and willing to participate in study 5. able to keep eyes still for 6 minutes exclusion criteria: 1. clinically documented hearing issues (e.g. in-ear hearing problems, punctured ear drum, etc.) 2. score of 7 or lower on the mini mental state exam (mmse) - orientation subscale 3. implanted pacemaker 4. metal or plastic implants in skull 5. in-ear hearing aid or cochlear implant, hearing device 6. recent (within last 6 months) acquired brain injury 7. history of other neurological disorder (e.g. brain cancer, dementia, multiple sclerosis, stroke, etc.) 8. exposed to investigational drug or device 30 days prior to start in this study, or concurrent use of investigational drug or device while enrolled in this study 9. not fluent in english language 10. unable to provide informed consent 11. previous participation in studies using the neurocatch platform™ 12. if female and of child-bearing potential: pregnant, suspected or planning to become pregnant or breast-feeding 13. history of seizures 14. allergy to rubbing alcohol or eeg gel
computerized neuropsychology in idiopathic normal pressure hydrocephalus (inph)

Conditions: Normal Pressure Hydrocephalus

Summary: a computerised neuropsychological test battery to be used as a standardised tool assessing the cognitive domains affected by idiopathic normal pressure hydrocephalus inph was developed. the aim of this study is to investigate the reliability, validity and feasibility of the battery.


Eligibility criteria:
inclusion criteria: * probable inph under investigation * healthy elderly * various diseases exclusion criteria: * (healthy elderly) medications affecting nervous system * (healthy elderly)heart disease * (healthy elderly)diabetes * (healthy elderly)disease of the nervous system * (healthy elderly)mmse \< 28 * (healthy elderly)vascular risk factors (two of: 1 hypertension, 2 smoking or 3 hyperlipidemia) * (healthy elderly)serious disease that may shorten life expectancy * (various diseases) affected motor functions

Keywords: normal pressure hydrocephalus neuropsychological test assessment of cognitive disorders/dementia neuropsychological assessment
evaluation of a weight management program

Conditions: Obesity

Summary: this retrospective chart review and data abstraction will evaluate and quantify the effectiveness of a comprehensive weight management program. the hypothesis is that the program will positively affect weight, weight-related comorbidities and medication use.


Eligibility criteria:
inclusion criteria: * records of the first 40 study center participants who enrolled in the optifast program from january 1, 2006 through june 30, 2006 * records of subjects who completed the active weight loss phase of the program * records where data is available through the transitional phase of the program exclusion criteria: * concurrent use of appetite suppressants or other weight loss medications

Keywords: obesity meal replacement obesity treatment weight management
triamcinolone acetonide as an adjunctive to vpdt in armd.

Conditions: Age-Related Macular Degeneration

Summary: a 24 - month study looking at the the changes in visual acuity of patients receiving pdt therapy in conjunction with intravitreal triamcinolone.

this study will evaluate the effect of triamcinolone acetonide in conjunction with photodynamic therapy for the treatment of sub-foveal choroidal neovascular membranes secondary to age-related macular degeneration.

Eligibility criteria:
inclusion criteria: * individuals with predominantly classic, subfoveal cnv secondary to amd. * no previous pdt treatment in study eye. exclusion criteria: * cnv from conditions, other than amd. * other disease that could be responsible for decreased vision.

Keywords: amd triamcinolone macular degeneration
6-year follow-up data after the berberine intervention trial

Conditions: Colorectal Adenoma; Colorectal Cancer Control and Prevention; Colorectal Polyps

Summary: colorectal cancer (crc) is a common malignancy of the digestive tract, which constitutes a major public health burden. almost 90% of crc cases progress from precursor adenomatous polyps through adenoma-carcinoma sequence. endoscopic detection and removal of colorectal adenoma (cra) could reduce the incidence and mortality risk of crc, but the recurrence rate is still high. therefore, chemoprevention is quite important, not only solve the urgent public health problem, but also be cost-effective. in 2020, the investigators published a multicenter, randomized, double-blind, placebo-controlled clinical study (nct02226185) in the lancet gastroenterology \& hepatology. the result concluded that oral bbr for 2 years significantly reduced recurrence after endoscopic removal of cra (rr 0.77, 95%ci 0.66-0.91; p=0.001). bbr also has a significant preventive effect on all polypoid lesions, including adenomas and serrated lesions (adjusted rr 0.78, 95%ci 0.66-0.91; p=0.002) . does bbr still have a long-term protective effect on the recurrence of cra after discontinuation? that's what the investigators concerned. the present study is performed to observe and compare retrospectively the recurrence rate of cras in patients of the original bbr rct study (nct02226185) within 6 years after discontinuation of medication, including the overall recurrence rate of traditional adenomas within the first year, 1-3 years, 3-6 years, and the entire follow-up period of 6 years. the aim is to evaluate the long-term efficacy of bbr in preventing recurrence and carcinogenesis after endoscopic resection of cras.


Eligibility criteria:
inclusion criteria: participants who completed the previous berberine intervention study (nct02226185) exclusion criteria: no

Keywords: berberine colorectal adenoma colorectal cancer long term chemoprevention colorectal polyps
use of adipose tissue derived mesenchymal stem cells for knee osteoarthrosis

Conditions: Knee Osteoarthrosis

Summary: adipose tissue derived mesenchymal stem cells (atmsc) will be injected in patients diagnosed with knee osteoarthrosis

ten patients from both genders diagnosed with knee osteoarthrosis, will be enrolled according to specific inclusion and exclusion criteria. these patients will be injected with adipose tissue derived mesenchymal stem cells. then, they are followed by clinical assessment, laboratory investigations as well as magnetic resonance imaging (mri) of the injected knee.

Eligibility criteria:
inclusion criteria: severe koa stage iii or iv by laurance \& kellgren staging as judged by posterioranterior (pa) xray of the knee joint. willing to participate by signing the informed consent exclusion criteria: * sublaxation beyond 20 degrees of the bones of the knee joint * oral anticoagulants or heparin therapy * heart failure or arrhythmia * body mass index \> 35 * uncontrolled diabetes mellitus. * evidence of infectious diseases. * active infection * malignancy * pregnancy * anemia less than 11g/dl or thrombocytopenia less than 100,000 or leucopenia less than 3000. * unreliable patients * non-resident in jordan

Keywords: osteoarthrosis knee adipose tissue stem cells cell therapy
kn046 in subjects with advanced solid tumors and lymphoma

Conditions: Advanced Solid Tumors; Lymphoma

Summary: this is a phase ia/ib, open-label, multicenter, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of kn046 in subjects with advanced solid tumors and lymphoma .


Eligibility criteria:
inclusion criteria: 1. signed informed consent; willing and able to complete all required procedures of study. 2. with advanced-stage or metastatic tumor (unresectable) and experienced progression since last anti-tumor treatment; standard therapy is not available or rejected. 3. subjects must have at least one measurable lesion in advanced solid tumors, at least one measurable or assessable lesion in nk/t cell lymphoma. 4. ecog performance status of 0 or 1. 5. subject must have adequate organ function. 6. female patients and males with partners of childbearing potential should be using highly effective contraceptive measures (failure rate of less than 1% per year). contraception should be continued for a period of 24 weeks after dosing has been completed. 7. ability to comply with treatment, procedures and pk sample collection and the required study follow-up procedures. exclusion criteria: 1. known brain metastasis or other cns metastasis that is either symptomatic or untreated. 2. is currently participating or has participated in a study of an investigational drug within 4 weeks prior to the first dose of trial treatment. 3. patients who have received immune checkpoint proteins/antibody/medicine (including pd-1, pd-l1, etc) for treatment. 4. has interstitial lung disease, or a history of pneumonitis that required oral or intravenous glucocorticoids to assist with management. 5. subjects with active autoimmune diseases or history of autoimmune diseases should be excluded. 6. active hbv or hcv infection. 7. known hiv infection or known history of acquired immune deficient syndrome (aids). 8. any unresolved ctcae grade ≥ 2 toxicities from prior anti-cancer therapy with the exception of vitiligo, alopecia. 9. patients who have serious hypersensitive reaction to monoclonal antibodies, and have history of uncontrolled allergic asthma.
first in patient study for pf-06840003 in malignant gliomas

Conditions: Oligodendroglioma; Astrocytoma; Malignant Glioma

Summary: this study will evaluate the safety and tolerability of increasing doses of pf-06840003 in patients with malignant gliomas.


Eligibility criteria:
inclusion criteria: * diagnosis of who grade iv glioblastoma or who grade iii anaplastic gliomas * for patients with grade iv gbm, recurrent disease at the time of the first or second recurrence or progression. for patients with grade iii anaplastic gliomas, recurrent disease at the time of at least a first recurrence but no more than a fourth recurrence or progression * karnofsky performance score greater than or equal to 70% * adequate bone marrow, kidney and liver function exclusion criteria: * history of cns bleeding within 6 months of registration * previous anti-angiogenics or anti-vascular endothelial growth factor within 12 months of registration * requires treatment with high dose systemic corticosteroids defined as \>2 mg/day * radiation therapy within 12 weeks of registration

Keywords: gbm malignant glioma glioma anaplastic glioma astrocytoma ido ido1 pf-06840003
does acupressure help reduce nausea and vomiting in palliative care patients? formal study

Conditions: Nausea; Vomiting

Summary: pilot study completed - power calculation performed. now formal double blind randomized study comparing active with placebo wristbands for nausea in palliative care patients to be carried out.

terminally ill hospice in-patients suffering with nausea will be randomized to active or placebo acupressure bands. the study will last 3 days and they will be allowed to continue regular or have prn anti-emetics during the study. assessors and patients will both be blinded to whether they patients are receiving active or placebo bands.

Eligibility criteria:
inclusion criteria: 1. have a diagnosis of advanced cancer with an estimated prognosis of less than 1 year but more than 3 days. 2. describe their nausea as at least moderate on a likert scale or at have had at least one vomit per day for the last three days. 3. have an underlying cause for their nausea which is thought to be irreversible or the patient has made an autonomous choice not to proceed with treatment for any potentially reversible cause (for example surgery for obstruction or drainage of ascites). 4. can be male or female patients but must be over the age of 18. 5. have signed a consent form prior to entering the study. 6. if patients are taking corticosteroids the dosage should be stable for 3 days before and during the trial. 7. be thought to be well enough to complete the 3 day trial. exclusion criteria: 1. arm lymphoedema. 2. weakness, fatigue or confusion sufficient that patient is unable to take part. 3. previous history of acupuncture/acupressure for nausea or vomiting, or history of use of acupressure by a close relative. 4. history of parkinsonism or parkinsonism on examination. 5. patients will not be enrolled if they are sharing a room with another patient taking part in the study. 6. patients who are unable to read or comprehend the questionnaire or visual analogue scale.

Keywords: nausea vomiting emesis palliative terminal cancer
quadriceps function prior to anterior cruciate ligament reconstruction

Conditions: Rupture of Anterior Cruciate Ligament

Summary: patients who are diagnosed with an isolated tear of the anterior cruciate ligament and scheduled for arthroscopic reconstruction using bone-patellar tendon-bone autograft will be recruited to participate. all subjects will be invited to participate in 2 weeks (2 supervised sessions per week) prior to their surgery. each session will include supervised therapeutic exercises. subjects will be randomly assigned to receive continuous transcutaneous electrical nerve stimulation (tens) during each session or knee joint cryotherapy prior to each exercise session. the investigators will measure quadriceps function before and after this 2-week intervention (both sessions occur prior to reconstruction surgery). this study will also have a true control group that will not receive either exercise of modality intervention. the investigators will collect subjective and objective outcomes data at regularly scheduled post-operative visits.


Eligibility criteria:
inclusion criteria: 1. complete acl rupture 2. age 15-55 exclusion criteria: 1. persons who cannot tolerate knee joint tens. 2. persons who have a known allergy to cryotherapy 3. patients who are pregnant or who plan on getting pregnant during the 12-month follow-up period.

Keywords: anterior cruciate ligament acl
controls and healthy vasculature initiative

Conditions: Vascular And Immunologic Diseases; Healthy Volunteers

Summary: background: diseases involving blood, blood vessels, and immune systems are leading causes of death in the united states. researchers studying these diseases need to compare blood samples from both healthy and sick individuals. blood samples from healthy people are also used to establish what is normal when developing new tests for diseases and to make sure new testing equipment is working properly. objective: this natural history study will collect blood samples from healthy people. the blood will be used for various kinds of research. eligibility: healthy adults aged 18 years or older. pregnant or nursing women will be excluded. design: participants will have a telehealth visit or telephone call to review their medical history. they will come to the nih clinical center. they will have a needle inserted into a vein in their arm or hand. about 10 tablespoons of blood will be drawn through the needle. researchers may perform a complete blood count, a type of blood test that can help evaluate the participant s overall health. they may do a blood type test. the blood samples will also be used for genetic studies. some blood samples may be stored for use in future research. participants may choose to return for repeat visits for up to 10 years. review of their medical history may also be repeated at later visits. they will receive $50 per blood collection visit. ...

study description: this study will serve to provide tissue samples from individuals with healthy vasculature for mechanistic studies of vascular inflammation and thrombosis. objectives: primary objective: to collect samples from healthy volunteers to: * establish and validate technical assays and equipment (e.g. platelet aggregation, inflammasome activation, neutrophil extracellular trap formation, tissue factor activity, etc.) * establish normal physiologic mechanisms and parameters in samples from healthy volunteers (e.g. platelet function, circulating autoantibody titers, etc.) endpoints: this protocol does not have an outcome measure, but rather will be conducted in accordance with good clinical practices for human research solely for the purpose of obtaining blood samples to optimize assays, conduct mechanistic investigations, measure vascular biomarkers, and facilitate the study of vascular and immunologic diseases in patients enrolled in other studies.

Eligibility criteria:
* inclusion criteria: in order to be eligible to participate in this study, an individual must meet all of the following criteria: * stated willingness to comply with all study procedures * aged 18 years and older * ability of subject to understand and the willingness to sign a written informed consent document * self-reported in good general health exclusion criteria: an individual who, by self-report, meets the following criteria will be excluded from participation in this study: -current pregnancy or lactation

Keywords: sample collection vascular blood inflammation thrombosis natural history
use of standardized diagnostic imaging data for image fusion in the hybrid operating room

Conditions: Heart Valve Diseases

Summary: objectives: goal of the study is to investigate the potential benefit that transcatheter interventions such as transcatheter aortic valve implantation (tavi), mitraclip, left atrial appendage closure and catheter ablation can gain from multimodal image fusion techniques as they are available in the hybrid suite. both the heartnavigator and the echonav aim at decreasing the exposure to radiation and contrast agent, to shorten the operation time (efficacy), and to increase the quality of care (safety). this pilot study aims at observing these aims on a small patient population and a control group. number of subjects: 140 patients total in 6 groups: * mitraclip, left atrial appendage closure or catheter ablation with echonav (20, lead-in stage). * mitraclip randomized with echonav (25), mitraclip randomized without echonav (25). * tavi with heartnavigator lead in (10) * tavi randomized with heartnavigator (30), tavi randomized without heartnavigator (30).

medical device: heartnavigator: system for preoperative image-based assessment of aortic root geometry, planning of transcatheter aortic valve implantation, and intraoperative c-arm control. echonav: system for intraoperative registration of 3d echo images with x-ray fluoroscopy images.

Eligibility criteria:
inclusion criteria: * male and female patients over 18 years of age. * ability and willingness to give informed consent. * indication for tavi, mitraclip, catheter ablation or percutaneous closure of the left atrial appendage procedure performed in the hybrid or suite. * recent good quality cta (tavi patients only, no cta needed for echonav). exclusion criteria: * contraindications on ethical grounds, * women who are pregnant or breast feeding, * emergency cases, * contraindication or known hypersensitivity to contrast media which is unresponsive to pretreatment with steroids and antihistamines, * known renal insufficiency (gfr \< 50 ml/min) and patient is not on chronic hemodialysis (tavi patients only, no contrast agent is necessary during mitraclip and transseptal puncture), * contraindications for transesophageal echo (echonav patients only, tavi is possible without tee and tee is not needed for the heartnavigator), * known or suspected drug or alcohol abuse, * enrollment into a clinical trial within last 4 weeks if overlapping enrolment is not explicitly approved by ethics committee for the two trials, * patient is unable or unwilling to cooperate with the study protocol.

Keywords: tavi mitraclip image modality echocardiography angiography